share_log

13F-HR/A: Information required of institutional investment managers pursuant to Section 13(f) (Amendment)

SEC announcement ·  May 16 04:24
Summary by Futu AI
The United States Securities and Exchange Commission (SEC) in Washington, D.C. has issued a Notice of Effectiveness for Virpax Pharmaceuticals, Inc. The notice indicates that the company's Form S-1 has become effective as of May 14, 2024, at 5:00 P.M. This form is typically used by companies to register new securities for sale to the public, suggesting that Virpax Pharmaceuticals may be planning a public offering or similar transaction. The SEC's notice confirms the registration's approval, allowing the company to proceed with its offering.
The United States Securities and Exchange Commission (SEC) in Washington, D.C. has issued a Notice of Effectiveness for Virpax Pharmaceuticals, Inc. The notice indicates that the company's Form S-1 has become effective as of May 14, 2024, at 5:00 P.M. This form is typically used by companies to register new securities for sale to the public, suggesting that Virpax Pharmaceuticals may be planning a public offering or similar transaction. The SEC's notice confirms the registration's approval, allowing the company to proceed with its offering.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.